SLC6A3 and late-onset Parkinson disease: In the quantitative analysis study of [18F]FP-CIT PET, it was observed that DAT binding in the PD group was reduced by 70% in the contralateral posterior putamen compared to normal levels, aligning with the clinical symptoms.